- Entrada Therapeutics Announces $100 Million Registered Direct Offering
- Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
- Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
- Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Entrada Therapeutics Reports First Quarter 2024 Financial Results
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Promotes Nathan J. Dowden to President
- Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
- Entrada Therapeutics Reports Third Quarter 2023 Financial Results
More ▼
Key statistics
On Monday, Entrada Therapeutics Inc (TRDA:NMQ) closed at 17.11, -5.83% below its 52-week high of 18.17, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.12 |
---|---|
High | 17.27 |
Low | 16.73 |
Bid | 16.39 |
Offer | 17.60 |
Previous close | 16.98 |
Average volume | 139.13k |
---|---|
Shares outstanding | 36.97m |
Free float | 31.38m |
P/E (TTM) | 27.29 |
Market cap | 632.94m USD |
EPS (TTM) | 0.6273 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼